KR101431877B1 - Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes - Google Patents
Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes Download PDFInfo
- Publication number
- KR101431877B1 KR101431877B1 KR1020110036411A KR20110036411A KR101431877B1 KR 101431877 B1 KR101431877 B1 KR 101431877B1 KR 1020110036411 A KR1020110036411 A KR 1020110036411A KR 20110036411 A KR20110036411 A KR 20110036411A KR 101431877 B1 KR101431877 B1 KR 101431877B1
- Authority
- KR
- South Korea
- Prior art keywords
- fish
- antiviral
- fraction
- fish pathogenic
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 25
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 24
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 12
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 12
- -1 flavonoid compounds Chemical class 0.000 title claims abstract description 9
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 title claims description 7
- 241000700605 Viruses Species 0.000 title description 20
- 244000044283 Toxicodendron succedaneum Species 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 13
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 10
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 5
- 235000002568 Capsicum frutescens Nutrition 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 5
- 241001247145 Sebastes goodei Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002044 hexane fraction Substances 0.000 claims description 3
- 239000002036 chloroform fraction Substances 0.000 claims description 2
- 239000002034 butanolic fraction Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 7
- 239000000401 methanolic extract Substances 0.000 abstract description 2
- 241000219492 Quercus Species 0.000 abstract 1
- 235000019688 fish Nutrition 0.000 description 21
- 241000711804 Infectious hematopoietic necrosis virus Species 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000002904 solvent Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000972773 Aulopiformes Species 0.000 description 6
- 241000277275 Oncorhynchus mykiss Species 0.000 description 6
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000019515 salmon Nutrition 0.000 description 6
- 238000004440 column chromatography Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 4
- FNUPUYFWZXZMIE-HUUCEWRRSA-N fustin Chemical compound C1([C@@H]2[C@@H](C(C3=CC=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-HUUCEWRRSA-N 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RGNXWPVNPFAADO-NSIKDUERSA-N sulfuretin Chemical compound O1C2=CC(O)=CC=C2C(=O)\C1=C\C1=CC=C(O)C(O)=C1 RGNXWPVNPFAADO-NSIKDUERSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- 241000277331 Salmonidae Species 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 244000144974 aquaculture Species 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000003910 Baronia <angiosperm> Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FNUPUYFWZXZMIE-UHFFFAOYSA-N Fustin Natural products O1C2=CC(O)=CC=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 FNUPUYFWZXZMIE-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241001280377 Oncorhynchus tshawytscha Species 0.000 description 2
- 241000295697 Pimephales promelas Species 0.000 description 2
- 241000269908 Platichthys flesus Species 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- MJBPUQUGJNAPAZ-AWEZNQCLSA-N butin Chemical compound C1([C@@H]2CC(=O)C3=CC=C(C=C3O2)O)=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-AWEZNQCLSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000011990 fisetin Nutrition 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- RGNXWPVNPFAADO-UHFFFAOYSA-N sulfuretin Natural products O1C2=CC(O)=CC=C2C(=O)C1=CC1=CC=C(O)C(O)=C1 RGNXWPVNPFAADO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BGYPHYAFWDUNDD-UHFFFAOYSA-N 1h-benzimidazole;sodium Chemical compound [Na].C1=CC=C2NC=NC2=C1 BGYPHYAFWDUNDD-UHFFFAOYSA-N 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- MJBPUQUGJNAPAZ-UHFFFAOYSA-N Butine Natural products O1C2=CC(O)=CC=C2C(=O)CC1C1=CC=C(O)C(O)=C1 MJBPUQUGJNAPAZ-UHFFFAOYSA-N 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 241000277269 Oncorhynchus masou Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000009305 Pometia pinnata Species 0.000 description 1
- 235000017284 Pometia pinnata Nutrition 0.000 description 1
- 244000163427 Saccharum procerum Species 0.000 description 1
- 241000277288 Salmo trutta Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- JQOAQUXIUNVRQW-UHFFFAOYSA-N hexane Chemical compound CCCCCC.CCCCCC JQOAQUXIUNVRQW-UHFFFAOYSA-N 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/10—Culture of aquatic animals of fish
- A01K61/13—Prevention or treatment of fish diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Virology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biodiversity & Conservation Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 칠피의 메탄올 추출물과 이의 다양한 유기용매 추출분획물로부터 어류병원성 항바이러스 활성 플라보노이드계 화합물을 분리·정제하고, 상기 칠피 추출물 및 유기용매 추출분획으로부터 분리정제한 플라보노이드계 화합물의 어류병원성 항바이러스 활성을 개시한다.The present invention relates to a method for isolating and purifying a fish pathogenic antiviral active flavonoid compound from a methanol extract of quercus and various organic solvent extract fractions thereof and a method for isolating and purifying a fish pathogenic antiviral activity of a flavonoid compound isolated from the above- .
Description
본 발명은 플라보노이드계 화합물을 유효성분으로 포함하는 항바이러스활성 조성물에 관한 것으로 어류 바이러스성 질환의 예방, 치료 또는 억제용 항바이러스 조성물에 관한 것이다.
The present invention relates to an antiviral active composition comprising a flavonoid compound as an active ingredient, and to an antiviral composition for preventing, treating or inhibiting a viral disease of fish.
수산양식업에 있어 전 세계적으로 문제가 되고 있는 수산양식생물 질병의 국내 발생 현황을 살펴보면, 1990년대 전반의 발병률이 5% 미만에 불과하던 것이 1990년대 후반부터는 15% 내외로 증가하고 있으며, 고수온기에 주로 발생하던 질병들이 연중 발생하는 추세에 있다. 그 중에서도 난치성 바이러스성 전염병의 발생 증가에 의한 양식 어류의 피해가 증대되고 있으며, 약제 오남용에 의한 내성균의 출현 증가로 치료 효과가 저하되고 있는 실정이다. 특히, 최근에 들어서는 국외로부터의 양식용 종묘의 수입량 증가로 인하여 신종 외래 전염병의 유입 위험성이 증대되고 있으며, 감염 종묘의 이동에 의한 질병의 확산이 우려되고 있다. 특히, 연어 및 송어과 어류의 아이에치엔브이(infectious hematopoietic necrosis virus:IHNV), 아이피엔브이(infectious pacreatic necrosis virus:IPNV)의 감염에 의한 피해는 1970년대 이후 지속적으로 발생되고 있으나, 그 치료를 위해 사용되어질 수 있는 적절한 약품의 개발은 국내외를 막론하고 없는 실정이다.
In the case of aquatic aquaculture disease, which is a global problem in the aquaculture industry, the incidence rate in the first half of the 1990s was only less than 5%, and it increased to around 15% in the late 1990s. The most common diseases are in the year-round trend. Among them, the damage of cultured fish due to the incidence of intractable viral infectious diseases is increasing, and the therapeutic effect is lowered due to the increase of the occurrence of resistant bacteria by abuse of medicines. Especially, recently, the increase of imports of cultivated seeds from overseas has increased the risk of introduction of new outbreak infectious diseases, and the spread of diseases due to the movement of infectious seedlings is concerned. In particular, the damage caused by infection of infectious hematopoietic necrosis virus (IHNV) and infectious pacreatic necrosis virus (IPNV) in salmon, trout and fish has been continuing since the 1970s, The development of appropriate drugs that can be used has not occurred at home or abroad.
어류에 치사성을 가진 산업적으로 중요한 질병을 일으키는 바이러스 중에서 분리배양이 가능한 질병으로서는 연어과 어류의 전염성조혈기 괴사 바이러스[infectious hematopoietic necrosis virus(IHNV)]가 원인이 되어지는 전염성 조혈기 괴사병 [infectious hematopoietic necrosis disease(IHND)], 전염성 췌장 괴사 바이러스[infectious pacreatic necrosis virus(IPNV)]가 원인으로 작용하는 전염성 췌장 괴사병[infectious pacreatic necrosis disease(IPND)]와 바이러스성 출혈성 폐혈 바이러스[viral hemorhagic septicemia virus(VHSV)]의 원인에 의한 바이러스성 출혈성 폐혈병[viral hemorhagic septicemia disease(VHSD)]가 가장 널리 알려져 있고 전 세계적으로 그 피해 또한 가장 심각한 질병으로 알려져 있다.
Among the viruses that cause lethal and industrially important diseases in fish are the infectious hematopoietic necrosis disease (IHNV) caused by the infectious hematopoietic necrosis virus (IHNV) of salmon and fish. (IPND) and viral hemorrhagic septicemia virus (VHSV), which are caused by infectious pac- tic necrosis virus (IPNV) (VHSD) is the most prevalent disease in the world and its damage is also known to be the most serious disease worldwide.
아이에치엔브이(IHNV)는 1969년 Amend 등에 의해서 무지개송어에서 처음으로 분리 보고되어진 바이러스로서 우리나라에서는 양식산 무지개송어 치어에서 1992년 처음 보고되어졌다. 병어의 신장과 비장, 특히 신장의 조혈조직에 심한 괴사가 주요 특징으로 원인바이러스는 포탄형의 형태를 보이고, 평균크기는 길이 160~180 nm, 직경 80~90 nm의 랩도바이러스과 노비랩도바이러스속으로 분류되어져있다(van Regenmortel et al., 2000). 아이에치엔브이(IHNV)에 의한 사망률은 70~80%에 달한다. 무지개송어, 산천어, 송어에 피해가 크다. 본 병은 발견당시 미국 서해연안의 홍연어 및 치눅 살몬(chinook salmon)의 풍토병적인 성격을 갖는 것으로 생각했었지만 무지개송어에서의 발증이 확인된 이후, 미국 각지에서 발생이 확인되어 1970년대에 일본 및 대만, 1990년대에 유럽각지로 확대되었다.
The IHNV was first reported in 1969 by Amend et al. In rainbow trout. It was first reported in 1992 in Korea in the breeding rainbow trout. The major features of the kidneys and spleen, particularly in the kidney hematopoietic tissues, of the pathogenesis are virus-like shell-like morphology. The average size of the virus is between 160 and 180 nm and between 80 and 90 nm in diameter. (Van Regenmortel et al., 2000). The death rate from IHNV is 70 to 80%. Rainbow trout, mountain fish, trout damage is large. This disease was thought to have an endemic nature of red sea salmon and chinook salmon on the west coast of the United States at the time of its discovery, but since the occurrence of rainbow trout was confirmed, , And expanded throughout Europe in the 1990s.
VHS에 관해서는 예전부터 무지개송어의 신종창(Nierenschwellung), 전염성 신종창간병성증(Infektiose Nierenschwellung und Leberdegeneration=INuL)등으로 불리어져왔다(Sch, 1954; Heutschmann, 1952). 1962년 국제수역기구(Office International des Epizooties:OIE)의 어병 심포지움에서 보고되었고(Jensen, 1963), 원인바이러스를 바이러스성 출혈성 폐혈 바이러스[Viral hemorrhagic septicemia virus(VHSV)]로 정하였다. VHS는 유럽, 북미, 아시아 지역에 매우 널리 발병하며, 무지개송어, 은연어, 강송어, 브라운송어, 스틸헤드 트로우트(steelhead trout) 등의 연어과 어류뿐만 아니라 대구, 청어등과 같은 자연수계의 어류 및 넙치등과 같은 해산양식어류에서도 널리 발생하여 그 피해가 매우 심각히 우려되어지고 있다. 원인체인 브이에치에스브이는 길이 160~180 nm, 직경 70~80 nm의 포탄형으로, ss-RNA바이러스로서 노비렙도바이러스속에 분류되어 있다(van Regenmortel et al., 2000). 폐사율은 조건에 따라 큰 폭으로 변하지만, 일반적으로 20~80%의 범위로 피해를 입힌다.
VHS has traditionally been referred to as the Nierenschwelung and Infectiose Nierenschwald und Leberdegeneration (Schu, 1954; Heutschmann, 1952) in rainbow trout. It was reported in the 1962 Fisheries Symposium of the Office International des Epizooties (OIE) (Jensen, 1963) and the causative virus was defined as the viral hemorrhagic septicemia virus (VHSV). VHS is very prevalent in Europe, North America and Asia, and it is widely used in fisheries such as salmon and fish such as rainbow trout, silver salmon, river trout, brown trout, steelhead trout, And also in marine aquaculture fish such as flounder, and the damage is very serious. Causes Chain V efectiviruses are of the shell type with a length of 160-180 nm and a diameter of 70-80 nm and are classified as ss-RNA viruses in the novidepod virus (van Regenmortel et al., 2000). Mortality rates vary widely depending on conditions, but generally range from 20 to 80%.
연어과어류의 주요 병원체인 아이에치엔브이, 아이피엔브이 및 브이에치에스브이의 감염예방법의 일환으로 백신개발의 연구가 진행되어 불활화백신, 약독화생백신, 성분백신 그리고 DNA백신 등 활발한 연구가 진행되어 왔으며(Fryer et al.(1976); Fukuda et al(1989a,b); Gilmore et al., 1988; LaPatra et al., 2002), 일부는 예방백신으로 적용되어지고 있다. Studies on the development of vaccines have been conducted as part of the infection control method of AICENV, IPENV, and VITECHV, the main pathogens of salmon and fish, and active research such as inactivated vaccine, live attenuated vaccine, (Gilmore et al., 1988; LaPatra et al., 2002) and some have been applied as prophylactic vaccines (Fryer et al., 1976; Fukuda et al.
아울러 어체 바이러스 보유어가 존재하는 수계에서는 수평감염이 일어날 가능성이 있으므로 전파방지를 위해 시설의 소독과 바이러스가 없는 용수의 확보, 난의 소독 등이 연구되어 적용되어지고 있다(Amend and Pietsch 1972; 吉水, 笠井, 2002). 하지만 감염어의 치료를 목적으로 적용되어질 수 있는 약제의 개발에는 큰 성과가 보고 되어지고 있지 않은 실정이다.
In order to prevent the spread of viruses, disinfection of facilities, securing of virus free water, and disinfection of eggs have been studied and applied (Amend and Pietsch 1972; Yoshitsu, Kasai, 2002). However, there have been no reports on the development of drugs that can be applied for the treatment of infectious diseases.
아이에치엔브이 및 브이에치에스브이의 화학요법에 관련해서는 항바이러스제인 소디움 벤지미다졸(sodium benzimidazole)을 40 ug/ml 이상으로 처리하여 에프에치엠[Fathead Minnow (FHM)]세포에서의 바이러스의 증식을 억제했지만(Amend, 1976), in vivo 실험은 아직 실행되지 않았다. 또한 양어지나 하천에서 분리한 세균의 배양액이나 허브, 한방생약에 항 아이에치엔브이활성이 발견되었고, in vivo에서도 효과가 인정되었었지만(Direkusarakom, 1996) 아직 실용화에 이르지는 못하였다. 1999년 Fabregas등은 수종의 해양미세조류배양농축액을 이용하여 브이에치에스브이의 증식저해를 조사하여 그 사용가능성을 제시한 예가 있으나 그 이후의 연구결과는 발표되어지고 있지 않는 것으로 사료된다.
Regarding the chemotherapy of Aiechen V and Viechs V, sodium benzimidazole, an antiviral agent, was treated at 40 ug / ml or higher to inhibit the virus in Fathead Minnow (FHM) cells (Amend, 1976), but in vivo experiments have not been performed yet. In addition, the anti-iethenzyme activity was found in culture media, herbs and herbal medicines of bacteria isolated from sheep or river, and the effect was recognized in vivo (Direkusarakom, 1996). In 1999, Fabregas et al. Reported the possibility of using viable microalgae culture concentrates to investigate the proliferation inhibition of V. aeruginosa. However, the results of this study have not been published yet.
칠피는 옻나무과(Anacardiaceae)에 속하는 옻나무 (Rhus verniciflua Stokes)의 수피이다. 옻나무는 중국, 일본 등 동북아시아에서 많이 자라는 낙엽활엽수교목으로 이의 수피 (bark)인 칠피로부터는 현재까지, 캘콘(chalcone), 플라보노이드(flavonoids) 등의 페놀성 화합물이 분리·보고 되어있고, 그 생리 활성으로는 근래에 칠피 추출물 또는 이로부터 분리된 페놀성 화합물들의 항암, 항염증, 항산화, 간세포보호활성, 항-아포토시스(Anti-apoptosis), 면역조절활성이 극소수 보고되어 있다. The chili pepper was classified into Rhus ( Rhus ) belonging to the Anacardiaceae verniciflua Stokes) bark. The lacquer tree is a deciduous broad-leaved arboreous tree that grows widely in Northeast Asia such as China and Japan. The phenolic compound such as chalcone, flavonoids and the like has been isolated and reported from the bark of bark, Recently, there have been only a few reports of anticancer, anti-inflammatory, antioxidant, hepatocyte protective activity, anti-apoptosis, and immunomodulating activity of the extracts of the present invention or the phenolic compounds separated therefrom.
현재까지 칠피 추출물이나 이로부터 분리된 화합물의 어류 병원체에 대한 항감염 활성에 관해서는 강(Kang)의 문헌(J. Fish Pathol., 18 (3): 227-237, 2005; 전남대학교석사학위논문, 2007) 등에서 어류병원성 세균에 대한 in vitro 항균활성 및 이의 in vivo 면역증강활성이 유일하게 보고 되어 있을 뿐이며, 어류의 병원성 virus에 대한 활성여부에 대하여는 지금까지 연구결과가 보고된 바 전혀 없는 실정이다.
To date, the anti-infectivity of fish extracts and their isolated compounds against fish pathogens has been reported in Kang's (J. Fish Pathol., 18 (3): 227-237, 2005; , 2007) and the like in In vitro antimicrobial activity and its in vivo immune enhancing activity have only been reported. No studies on the activity of the fish against pathogenic viruses have been reported so far.
따라서, 본 발명은 칠피추출물 및 이로부터 분리한 분획물의 어류병원성 바이러스 활성을 검증, 확인하는 데 그 목적이 있다.
Accordingly, the object of the present invention is to verify and confirm the fish pathogenic viral activity of the extract of horseradish and the fraction isolated therefrom.
상기 본 발명의 상기 목적은 칠피 유기용매 추출물을 제조하는 단계와; 칠피추출물을 증류수에 현탁하고 비극성 용매 분획물을 수득하는 단계와; 상기 분획물별 어류 항바이러스 활성을 검증하는 단계 및; 에틸아세테이트 분획물로부터 분광분석을 실시하여 플라보노이드게 화합물을 분리동정하고 어류 항바이러스 활성을 측정 평가함으로써 달성하였다.
The above object of the present invention can be achieved by a method for producing an organic solvent extract, Suspending the horsetail extract in distilled water and obtaining a non-polar solvent fraction; Verifying the fish antiviral activity by said fraction; Ethyl acetate fractions were subjected to spectral analysis to isolate and identify flavonoid crab compounds and to measure and evaluate fish antiviral activity.
본 발명은 칠피 유래의 어류 항바이러스 활성 플라보노이드계 화합물을 제조하는 효과가 있으며, 이를 이용하여 적기에 어류 난치성 바이러스 질환의 예방 및 치료를 실시하여 퇴치함으로써 어업의 안정성을 기대할 수 있는 뛰어난 효과가 있다.
The present invention has an effect of producing a fish antiviral active flavonoid compound derived from chili pepper, and using this, it has an excellent effect that the stability of fishery can be expected by preventing and treating fish refractory viral diseases at a proper time and eliminating them.
도 1은 본 발명 칠피 추출물로부터 플라보노이드계 화합물들을 분리정제하기 위한 유기용매 추출과정을 보인 공정도이다.
도 2는 본 발명 에틸아세테이트 분획(도 1 참조)으로부터 활성분획을 얻는 과정을 보인 공정도이다.
도 3은 본 발명 플라보노이드계 화합물을 최종분리정제하여 얻은 소분획물의 유효성분의 화합물들이다.FIG. 1 is a process diagram showing an organic solvent extraction process for separating and purifying flavonoid compounds from the extract of the present invention.
FIG. 2 is a process diagram showing a process for obtaining an active fraction from the ethyl acetate fraction of the present invention (see FIG. 1).
Fig. 3 shows the compounds of the active ingredient of the small fraction obtained by final purification and purification of the flavonoid compound of the present invention.
<실시예 1> 칠피 추출물의 제조≪ Example 1 > Preparation of chili pepper extract
건조 및 조말한 칠피 6.75kg을 80% 메탄올(MeOH)로 99분씩 초음파 추출을 3회 실시한 후, 추출액 33L을 모아 진공 농축기(vacuum evaporator)로 감압농축하고 동결건조하여 이후의 분리 및 활성시험을 위한 시료로 사용하였다(도 1).
6.75 kg of dried and chopped chili pepper were subjected to ultrasonic extraction three times for 99 minutes with 80% methanol (MeOH), and then 33 L of the extract was collected, concentrated under reduced pressure using a vacuum evaporator, lyophilized, And used as a sample (Fig. 1).
<실시예 2> 칠피 비극성용매 분획물의 제조Example 2: Preparation of a non-polar solvent fraction of paper
상기 실시예 1에서 추출한 80% MeOH 추출물(97.6g)을 증류수에 현탁한 후, 헥산 (n-hexane), 클로로포름 (chloroform, CHCl3), 에틸 아세테이트 (ethylacetate, EtOAc), 및 수포화 부탄올 (n-butanol, n-BuOH)의 순으로 유기용매의 극성을 높여가며 순차적으로 분획을 실시하여 총 5개의 분획물을 얻었다(도 1). 상기에서 얻은 총 5개의 분획물에 대하여 어류병원성바이러스 IHNV 및 VHSV에 대한 항바이러스활성을 검색한 결과, SI값만을 비교하여 보았을 때는 IHNV 에 대해서는 에틸 아세테이트 분획물이 가장 우수한 활성을 나타내었고, VHSV에 대해서는 헥산분획물을 제외한 네가지 분획물에서 고른 활성을 나타내는 것으로 판단되었다(표 1).
After the 80% MeOH extract (97.6g) extracted in Example 1 was suspended in distilled water, hexane (n -hexane), chloroform (chloroform, CHCl 3), ethyl acetate (ethylacetate, EtOAc), and saturated butanol (n -butanol, and n- BuOH) in the order of increasing the polarity of the organic solvent, followed by sequential fractionation to obtain a total of five fractions (FIG. 1). As a result of screening the antiviral activities against fish pathogenic viruses IHNV and VHSV in the total of 5 fractions obtained above, the ethyl acetate fraction showed the best activity for IHNV and the hexane (Table 1). ≪ tb >< TABLE >
<실시예 3> 에틸 아세테이트 분획물로부터 활성화합물의 분리 Example 3 Isolation of Active Compound from Ethyl Acetate Fraction
상기 실시예 2에서 두 바이러스에 대하여 모두 우수한 항바이러스활성을 나타낸 에틸 아세테이트 분획물로부터 활성화합물 분리를 시도하였다(도 2). 상기 에틸 아세테이트 분획물 25g에 대한 MPLC (solvent: water:MeOH 95:5, 90:10, 85:15, 80:20, 75:25, 30:70, 20:80, 0:100/ column: 250g RediSep reversed phase C-18 column Teledyne Iso, USA)를 실시하고 TLC 결과에 따라 major spot을 중심으로 9개의 소분획으로 나누었다. 각 소분획물로부터 아래와 같은 방법으로 화합물을 분리하였다.
In Example 2, active compounds were separated from the ethyl acetate fraction showing excellent antiviral activity against both viruses (Fig. 2). The ethyl acetate fraction was subjected to MPLC (solvent: water: MeOH 95: 5, 90:10, 85:15, 80:20, 75:25, 30:70, 20:80, 0: 100 / column: 250 g RediSep reversed phase C-18 column Teledyne Iso, USA) and divided into 9 subfractions centered on the major spot according to the TLC results. The compounds were separated from each of the fractions in the following manner.
① 소분획물 Ⅱ ① Small fraction II
소분획물 Ⅱ (2.19g)는 ODS column chromatography (solvent: water:MeOH = 100:0, 98:2, 96:4, 94:6, 92:8, 90:10, 88:12, 0:100/ column: 40×120mm)를 실시하였으며, 이로부터 얻은 소분획물 1번으로 MPLC (solvent: 100% water/ column: 130g RediSepRreversedphaseC-18column)를 실시하여 화합물 1 (230mg)을 분리하였다 (도 2 및 도 3). 100: 0, 98: 2, 96: 4, 94: 6, 92: 8, 90:10, 88:12, 0: 100 / Column: 40 × 120 mm), and Compound 1 (230 mg) was isolated by MPLC (solvent: 100% water / column: 130 g RediSep R reversedphase C-18 column) 3).
② 소분획물 Ⅲ② Small fraction Ⅲ
소분획물 Ⅲ (3.55g)은 Sephadex™ LH-20 column chromatography (solvent: MeOH:water = 95:5/ column: 15×1300mm)를 실시하였으며, 이로부터 얻은 소분획물 5번을 다시 Sephadex™ LH-20 column chromatography (solvent: 100% MeOH)를 실시하여 6개의 소분획물을 얻었다. 소분획물 3번으로 MPLC (solvent: water: Acetoniltril = 90:10/ column: 43g RediSepRreversedphaseC-18column)를 실시하여 화합물 2 (48.5mg)를 분리하였다 (도 2 및 도 3). The small fraction (3.55 g) was subjected to Sephadex LH-20 column chromatography (solvent: MeOH: water = 95: 5 / column: 15 × 1300 mm) column chromatography (solvent: 100% MeOH) to obtain six small fractions. Compound 2 (48.5 mg) was isolated by performing MPLC (solvent: water: Acetonitrile = 90: 10 / column: 43 g RediSep R reversedphase C-18 column) with small fraction No. 3 (FIGS. 2 and 3).
③ 소분획물 Ⅴ ③ Small fraction Ⅴ
소분획물 Ⅴ(4.24g)는 Sephadex™ LH-20 column chromatography (solvent: 100% MeOH/ column: 15×1300mm)를 실시하여 화합물 3 (285.5mg)을 얻었고, 그 외의 주요 소분획물들을 합쳐서 MPLC (solvent: water: MeOH=90:10, 80:20, 70:30, 60:40, 40:60, 30:70, 20:80, 0:100/ column: 43g RediSepRreversedphaseC-18column)를 실시하여 화합물 4 (62.1mg)를 얻었다 (도 2 및 도 3).
The fraction (V) (4.24 g) was subjected to Sephadex LH-20 column chromatography (solvent: 100% MeOH / column: 15 × 1300 mm) to obtain Compound 3 (285.5 mg). The other major fractions were combined, : water: MeOH = 90:10, 80:20, 70:30, 60:40, 40:60, 30:70, 20:80, 0: 100 / column: 43 g RediSep R reversedphase C-18 column) 4 (62.1 mg) was obtained (Fig. 2 and Fig. 3).
④ 소분획물 Ⅵ ④ Small fraction Ⅵ
소분획물 Ⅵ (5.29g)은 Sephadex™ LH-20 column chromatography (solvent: 100% MeOH/ column: 15×1300mm)를 실시하였으며, 이로부터 얻은 5번 소분획물을 다시 Sephadex™ LH-20 column chromatography (solvent: 100% MeOH/ column: 15×1300mm)를 실시하여 화합물 5 (85mg)을 얻었다. 또한 소분획물 7번을 Sephadex™ LH-20 column chromatography (solvent: 100% MeOH/ column: 15×1300mm)를 실시하여 화합물 6 (41.3mg)를 얻었다 (도 2 및 도 3).
The small fraction 5 (5.29 g) was subjected to Sephadex ™ LH-20 column chromatography (solvent: 100% MeOH / column: 15 × 1300 mm) : 100% MeOH / column: 15 x 1300 mm) to obtain Compound 5 (85 mg). The fraction 7 was further subjected to Sephadex LH-20 column chromatography (solvent: 100% MeOH / column: 15 x 1300 mm) to obtain Compound 6 (41.3 mg) (FIGS. 2 and 3).
<실시예 4> 화합물의 화학구조 분석 및 동정Example 4 Analysis and Identification of Chemical Structures of Compounds
본 발명 상기 화합물의 화학구조를 분석하기 위하여, EIMS/FABMS, 1H-NMR 및 13C-NMR 등을 이용한 분광학적 분석을 실시하였다. 그 결과, 화합물 1~6은 각각의 문헌치와 비교하여 methyl gallate (1), fustin (2), fisetin (3), butin (4), sulfuretin(5) 및 butein (6)으로 동정되었다(도 3).
In order to analyze the chemical structure of the compound of the present invention, spectroscopic analysis was performed using EIMS / FABMS, 1 H-NMR and 13 C-NMR. As a result, the compound 1-6 was identified as methyl gallate (1), fustin ( 2), fisetin (3), butin (4), sulfuretin (5) and butein (6) as compared with respective reference values (FIG. 3).
<실험예 1> 칠피 추출물 및 분획물의 항바이러스 활성≪ Experimental Example 1 > Antiviral activity of extracts and fractions of horseradish
주화세포배양Coin cell culture
바이러스 배양을 위한 어류주화세포는 씨에치에스이-214[Chinook Salmon Embryo-214(CHSE-214)]와 에프에스피[Flounder Spleen(FSP)] 세포를 최소기초배지[Eagle's minimum essential medium(MEM)]에 100 IU/m의 페니실린(penicillin), 100 ug/ml의 스트렙토마이신(streptomycin)과 에프비에스[Fetal Bovine Serum(FBS)]가 10% 첨가된 배양액을 사용하여 각 플라스크에 2.5×105/ ml로 맞추어 20℃에서 6시간 동안 배양한 후 바이러스 접종에 사용하였다.
Fish coin cells for virus cultures were obtained by seeding Chinook Salmon Embryo-214 (CHSE-214) and Flounder Spleen (FSP) cells in Eagle's minimum essential medium (MEM) Ml of streptomycin and 10% of Fetal Bovine Serum (FBS) was added to each flask at a concentration of 2.5 x 10 < 5 > / ml And incubated at 20 ° C for 6 hours.
바이러스 배양Virus culture
실험에 사용한 바이러스주는 아이에치엔브이 (IHNV, RtPy91), 및 브이에치에스브이 (VHSV, Wando 2005)를 사용하였다. 바이러스는 stock을 위해 씨에치에스이-214 cell line에 엠오아이[Multiplicity Of Infection (M.O.I)]가 0.01로 되게 접종하고 20℃에서 5일간 배양하면서 세포변성효과[Cytopathic effect (CPE)]를 관찰 한 후 상등액을 마이크로튜브에 분주하여 실험에 사용하기 전까지 -80℃에서 보관하였다.
The viral strains used in the experiments were Iechniv (IHNV, RtPy91), and VeeVIS (VHSV, Wando 2005). The virus was inoculated into the seeds of the E. elegans -214 cell line for MOI of 0.01 and then cultured at 20 ° C for 5 days to observe the cytopathic effect (CPE) The supernatant was dispensed into microtube and stored at -80 ° C until use in the experiment.
세포독성조사Cytotoxicity investigation
96-well cell culture plate에 씨에치에스이-214 및 에프에스피 주화세포를 배양하여 시료를 가한 후 48시간동안 배양하여 neutral red uptake assay로 세포독성을 측정하였다. 각 농도별 세포독성을 plotting하여 CC50 (50% cytotoxic concentration)을 구하였다. 또한, 현미경상으로 독성을 나타내지 않는 최고농도 MNCC (maximal non-cytotoxic concentration)로서도 시료의 세포독성을 나타내었다. 각 시료의 항바이러스활성은 세포독성을 전혀 나타내지 않는 농도범위에서 측정되었다.
Cells were cultured in 96-well cell culture plates, cultured for 48 hours, and cytotoxicity was measured by neutral red uptake assay. CC 50 (50% cytotoxic concentration) was determined by plotting cytotoxicity at each concentration. In addition, the maximum cytotoxic concentration of MNCC (maximal non-cytotoxic concentration), which does not show toxicity by microscopic observation, also showed the cytotoxicity of the sample. The antiviral activity of each sample was measured in a concentration range that did not show any cytotoxicity.
항바이러스 활성 측정Antiviral activity measurement
CPE (cytopathic effect) reduction assay를 이용하여 시료의 항바이러스 활성을 측정하였다. 간략히 설명하면, 96well plate에 배양된 세포에 바이러스희석액과 시료를 1:1로 섞어 quadruplicate로 15℃에서 배양하였다. 5-6일 이후 바이러스 control구에서 바이러스에 의한 세포변성 (CPE)이 모든 well에서 고르게 나타나게 되면 배양을 중지하고 그 때의 각 시료구의 CPE를 현미경으로 관찰하여 virus control 구의 CPE와 비교하여 scoring 하였다. CPE를 50% 감소시키는 농도 (EC50)은 각 농도별 CPE reduction (%)를 그래프에 plotting 하여 구하였다.
The antiviral activity of the sample was measured using a CPE (cytopathic effect) reduction assay. Briefly, cells incubated on a 96-well plate were mixed with virus diluent and sample 1: 1 and incubated at 15 ° C with quadruplicate. After 5 to 6 days, when virus denaturation (CPE) was observed in all wells, the culture was stopped and the CPE of each sample was observed under a microscope and scored compared to the CPE of the virus control. Concentration (EC50), which reduces CPE by 50%, was obtained by plotting CPE reduction (%) for each concentration on the graph.
칠피 추출물과 이의 하위분획물에 대하여 항바이러스 활성을 측정평가 결과, 칠피의 80% 메탄올추출물의 SI값은 IHNV 및 VHSV 에 대하여 각각 15.0, 19.1로 나타났다. IHNV에 대한 항바이러스 활성은 하위분획물 중 에틸아세테이트 분획물에서 상대적으로 가장 높게 나타났으며, 헥산분획물은 EC50값에 비해 상대적으로 높은 독성으로 인하여 낮은 SI 값을 나타내었다. VHSV에 대해서는 헥산 분획물을 제외한 나머지 네분획물에서 고른 항바이러스활성을 나타내었다. 그중 클로로포름 분획물과 에틸아세테이트분획물에서는 EC50이 각각 1.8 및 3.6 μg/mL으로 우수한 효과를 나타내었고 이들의 SI값은 각각 31.7 및 21.9로 나타났다(표 1). The antioxidant activities of the extracts of Arnoldschrift and its fractions were 15.0 and 19.1 for IHNV and VHSV, respectively. The antiviral activity against IHNV was the highest in the ethyl acetate fraction of the lower fraction and the hexane fraction had a lower SI value due to the relatively higher toxicity than the EC50 value. For VHSV, the antiviral activity was exhibited in the remaining four fractions except for the hexane fraction. In the chloroform fraction and the ethyl acetate fraction, the EC50 values were 1.8 and 3.6 μg / mL, respectively, and the SI values were 31.7 and 21.9, respectively (Table 1).
<실험예 2> 칠피 에틸아세테이트분획물에서 분리된 화합물들의 항바이러스 활성<Experimental Example 2> Antiviral activity of the compounds isolated from the ethyl acetate fraction
분리한 페놀계 화합물들의 항바이러스 활성을 상기 실험예1에서과 동일하게 실시하였다. The antiviral activity of the separated phenol compounds was measured in the same manner as in Experimental Example 1.
실험결과, 표 2에서와 같이 fisetin (3)이 IHNV 및 VHSV에 대하여 모두 가장 높은 항바이러스활성을 나타내었다. 그 외, fustin (2)과 sulfuretin (5)도 두 바이러스에 대한 우수한 항바이러스 활성을 나타내었다. 분리된 6종의 화합물 중 methyl gallate 및 butein을 제외한 4종의 화합물은 500 내지 1000μM에서도 독성이 50% 이하로 나타났으며 그 이상의 농도에서는 용해도 문제로 세포독성 시험을 실시하지 못하였다. 현재 인체용 항바이러스약물로 사용중인 ribavirin을 positive control로 함께 시험하여 그 효과를 비교하였다. 그 결과, 본 발명에서 제시한 플라보노이드들의 EC50값은 ribavirin보다 현저히 높으나, ribavirin의 높은 세포독성은 어류세포주에서도 동일하게 나타남을 알 수 있으며, 이러한 ribavirin의 단점을 보완해 줄 수 있는 새로운 구조의 항바이러스물질로서 플라보노이드 계열 화합물도 기본골격에 대한 후보물질로서 기여할 수 있을 것으로 판단된다. As shown in Table 2, fisetin (3) showed the highest antiviral activity against both IHNV and VHSV. In addition, fustin (2) and sulfuretin (5) showed excellent antiviral activity against both viruses. Of the six isolated compounds, the four compounds except methyl gallate and butein showed 50% or less toxicity even at 500 to 1000 μM, and no cytotoxicity test was conducted due to the solubility problem. Currently, ribavirin, which is used as a human antiviral drug, is tested with a positive control. As a result, the EC50 value of the flavonoids proposed in the present invention is significantly higher than that of ribavirin, but the high cytotoxicity of ribavirin is found to be the same in fish cell lines, and a novel structure of antiviral It is considered that the flavonoid-based compound as a substance can also contribute as a candidate substance to the basic skeleton.
본 발명은 칠피 메탄올 추출물 또는 그 에틸아세테이트 분획물을 유효성분으로 하는 신규한 어류병원성 항바이러스 조성물을 제공하는 뛰어난 효과가 있으므로 생물농약 및 기술집약형 어업상 매우 유용한 발명인 것이다.The present invention is an extremely useful invention in biological pesticides and technology-intensive fishing because it has an excellent effect of providing a novel fish pathogenic antiviral composition comprising an extract of chrysanthemum methanol or an ethyl acetate fraction thereof as an active ingredient.
Claims (4)
A composition for fish pathogenic antiviral comprising an extract obtained by ultrasonically extracting chili pepper with 80% methanol, or a fraction obtained by adding an organic solvent to the above extract again as an active ingredient
A composition for fish pathogenic antiviral comprising any one of the flavonoid compounds selected from the following structural formulas [1] to [6] as an active ingredient.
The composition according to claim 1, wherein the organic solvent fraction is selected from the group consisting of hexane, chloroform, ethyl acetate, and butanol fractions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110036411A KR101431877B1 (en) | 2011-04-19 | 2011-04-19 | Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110036411A KR101431877B1 (en) | 2011-04-19 | 2011-04-19 | Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120118805A KR20120118805A (en) | 2012-10-29 |
KR101431877B1 true KR101431877B1 (en) | 2014-08-25 |
Family
ID=47286154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110036411A Active KR101431877B1 (en) | 2011-04-19 | 2011-04-19 | Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101431877B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100349818B1 (en) * | 1994-01-20 | 2002-12-31 | 호아시 마사히토 | Antiviral powder, antiviral extract and preparations containing the powder and / or extract |
-
2011
- 2011-04-19 KR KR1020110036411A patent/KR101431877B1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100349818B1 (en) * | 1994-01-20 | 2002-12-31 | 호아시 마사히토 | Antiviral powder, antiviral extract and preparations containing the powder and / or extract |
Also Published As
Publication number | Publication date |
---|---|
KR20120118805A (en) | 2012-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xin et al. | Isolation of antofine from Cynanchum atratum BUNGE (Asclepiadaceae) and its antifungal activity against Penicillium digitatum | |
Kang et al. | Antiviral activities of flavonoids isolated from the bark of Rhus verniciflua stokes against fish pathogenic viruses in vitro | |
Yeh et al. | Evaluation of the antibacterial activity of leaf and twig extracts of stout camphor tree, Cinnamomum kanehirae, and the effects on immunity and disease resistance of white shrimp, Litopenaeus vannamei | |
Palanikumar et al. | Effect of Argemone mexicana active principles on inhibiting viral multiplication and stimulating immune system in Pacific white leg shrimp Litopenaeus vannamei against white spot syndrome virus | |
Luize et al. | Activity of Neolignans Isolated from Piper regnellii (M IQ.) C. DC. var. pallescens (C. DC.) Y UNCK against Trypanosoma cruzi | |
Kim et al. | In vitro antiviral activity of red alga, Polysiphonia morrowii extract and its bromophenols against fish pathogenic infectious hematopoietic necrosis virus and infectious pancreatic necrosis virus | |
KR101732022B1 (en) | Anti-Viral Compositions against Fish Pathogenic Virus comprising Extract or Fractions from Sanguisorba officinlis as Active Ingredient | |
CN105152895A (en) | New meroterpenoid as well as preparation method and medical application thereof | |
Chakraborty et al. | Screening, isolation and optimization of anti–white spot syndrome virus drug derived from marine plants | |
Uddin et al. | Antioxidant, antibacterial and cytotoxic activity of Caulerpa racemosa (Forsskål) J. Agardh and Ulva (Enteromorpha) intestinalis L. | |
Rahmasari et al. | Antiviral activity of Aspalathus linearis against human influenza virus | |
KR100838621B1 (en) | A composition containing extract of Morrow red thread having antiviral activity against fish pathogenic viruses and bromophenol-based compounds isolated therefrom | |
Esimone et al. | In vitro evaluation of the antiviral activity of extracts from the lichen Parmelia perlata (L.) Ach. against three RNA viruses | |
Wani et al. | Antibacterial and phytochemical screening of different extracts of five Iris species growing in Kashmir | |
KR101431877B1 (en) | Antiviral composition against fish pathogenic viruses comprising of flavonoid compounds from Rhus verniciflua Stokes | |
JPH0778021B2 (en) | Diarrhea virus infection inhibitor | |
Onocha et al. | Antileishmaniasis, phytotoxicity and cytotoxicity of Nigerian Euphorbiaceous Plants 2: Phyllanthus amarus and Phyllanthus muellerianus Extracts | |
CN104622853B (en) | A kind of application of Sesquiterpenoid of seaweed | |
Zhang et al. | Effect of Korean arbor vitae (Thuja koraiensis) extract on antimicrobial and antiviral activity | |
CN108913650A (en) | Application of chitosan selenium in inhibiting reduction of total antioxidant capacity of porcine endometrial epithelial cells caused by F-2 toxin | |
Krishnan et al. | Antiviral activity of dasyscyphin C extracted from Eclipta prostrataagainst fish nodavirus | |
Aslam et al. | Evaluation of antiviral effect of epigallocatechin gallate, epigallocatechin, epicatechin gallate and green tea extract against fowl adenovirus-4 | |
Castillo-Reyes et al. | Polyphenols extraction from creosote bush, tarbush, and soursop using ultrasound-microwave and their effect against Alternaria alternata and Fusarium solani | |
KR101084733B1 (en) | Composition for the prevention and treatment of hepatotoxic diseases containing teal stem extract or a compound isolated therefrom | |
Amman et al. | Determination of the post-antibiotic effect (PAE) of combinations of extracts from galls of Quercus infectoria with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20110419 |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130212 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20130826 Patent event code: PE09021S02D |
|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
E801 | Decision on dismissal of amendment | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20140328 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130826 Comment text: Final Notice of Reason for Refusal Patent event code: PE06011S02I Patent event date: 20130212 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
PE0801 | Dismissal of amendment |
Patent event code: PE08012E01D Comment text: Decision on Dismissal of Amendment Patent event date: 20140328 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20131028 Patent event code: PE08011R01I Comment text: Amendment to Specification, etc. Patent event date: 20130412 |
|
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20140328 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20131028 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20130412 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20140710 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20140424 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20140328 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20131028 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20130412 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20140812 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20140812 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20190730 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20190730 Start annual number: 6 End annual number: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20200728 Start annual number: 7 End annual number: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20210728 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20220726 Start annual number: 9 End annual number: 9 |
|
PR1001 | Payment of annual fee |
Payment date: 20230620 Start annual number: 10 End annual number: 10 |
|
PR1001 | Payment of annual fee |
Payment date: 20240620 Start annual number: 11 End annual number: 11 |